Puja B. Parikh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Puja B. Parikh has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
Thomas Bilfinger
Department of Surgery, Renaissance School of Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA
11 shared publications- Jignesh K. Patel
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY, USA
10 shared publications Smadar Kort
Department of Medicine, Stony Brook University Hospital, Stony Brook, New York
10 shared publicationsHenry Tannous
Department of Surgery, Renaissance School of Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA
8 shared publicationsLuis Gruberg
Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY, United States of America
8 shared publications- Afshin Ehsan
Brown University, Rhode Island Hospital
7 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in The American Journal of Cardiology
From Prognostication to Precision Resuscitation After In-Hospital Cardiac Arrest
- 30 September 2026
- Published by Elsevier in The American Journal of Cardiology
From Prognostication to Precision Resuscitation After In-Hospital Cardiac Arrest
- 15 April 2026
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Closure of symptomatic mitral paravalvular leak following recent transcatheter mitral valve-in-ring
An 86-year-old man who had undergone recent transcatheter mitral valve-in-ring at an outside hospital presented with multiple hospitalizations for symptomatic hemolytic anemia requiring blood transfusions. Transesophageal echocardiogram demonstrated mitral paravalvular leak originating laterally between the transcatheter valve and surgical ring. Clinical Images from Journal of Invasive Cardiology. mitral valve Paravalvular leak
- 15 April 2026
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Closure of symptomatic mitral paravalvular leak following recent transcatheter mitral valve-in-ring
An 86-year-old man who had undergone recent transcatheter mitral valve-in-ring at an outside hospital presented with multiple hospitalizations for symptomatic hemolytic anemia requiring blood transfusions. Transesophageal echocardiogram demonstrated mitral paravalvular leak originating laterally between the transcatheter valve and surgical ring. Clinical Images from Journal of Invasive Cardiology. mitral valve Paravalvular leak
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e014802
Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications
BACKGROUND: Patients with bicuspid aortic stenosis who receive transcatheter aortic valve replacement (TAVR) may require subsequent valve interventions in their lifetime; however, the feasibility of redo-TAVR in this population is uncertain. We aimed to assess redo-TAVR feasibility in bicuspid patients and develop a predictive virtual valve planning algorithm. METHODS: We studied computed tomography scans of bicuspid patients who received a balloon-expandable transcatheter heart valve (THV) in the LRT trial (Low Risk TAVR). Redo-TAVR feasibility, determined by valve-to-coronary and valve-to-aorta measurements on 30-day computed tomography, was assessed according to raphe location and calcification. A virtual valve planning algorithm was developed using baseline and 30-day computed tomography scans. RESULTS: Among 42 patients (left/right cusp fusion: n=34; right/noncusp fusion: n=4; 2-sinus: n=4), redo-TAVR was feasible in 64%, while 36% would likely require leaflet modification to prevent coronary obstruction. Patients with left/right fusion and calcified raphe had higher redo-TAVR feasibility (88% versus 35%, P <0.001) due to favorable shifting of the THV away from the coronary ostia. A bicuspid virtual planning algorithm accounting for 83.4% THV underexpansion, resulting in an 11.9% taller frame and translation of the THV away from the calcified raphe (mean valve shift 6.6 mm) achieved 86.7% sensitivity and 88.9% specificity for predicting redo-TAVR feasibility. CONCLUSIONS: Calcified raphe in left/right cusp fusion shifts the THV away from the coronary ostia, reducing coronary obstruction risk during redo-TAVR. Underexpansion causing increased THV frame height and valve shifting is common in bicuspid patients; a virtual planning algorithm accounting for these aspects can accurately assess redo-TAVR risk. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02628899.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e014802
Impact of Calcified Raphe on TAVR in Bicuspid Patients: Predicting Redo-TAVR Feasibility and Virtual Planning Implications
BACKGROUND: Patients with bicuspid aortic stenosis who receive transcatheter aortic valve replacement (TAVR) may require subsequent valve interventions in their lifetime; however, the feasibility of redo-TAVR in this population is uncertain. We aimed to assess redo-TAVR feasibility in bicuspid patients and develop a predictive virtual valve planning algorithm. METHODS: We studied computed tomography scans of bicuspid patients who received a balloon-expandable transcatheter heart valve (THV) in the LRT trial (Low Risk TAVR). Redo-TAVR feasibility, determined by valve-to-coronary and valve-to-aorta measurements on 30-day computed tomography, was assessed according to raphe location and calcification. A virtual valve planning algorithm was developed using baseline and 30-day computed tomography scans. RESULTS: Among 42 patients (left/right cusp fusion: n=34; right/noncusp fusion: n=4; 2-sinus: n=4), redo-TAVR was feasible in 64%, while 36% would likely require leaflet modification to prevent coronary obstruction. Patients with left/right fusion and calcified raphe had higher redo-TAVR feasibility (88% versus 35%, P <0.001) due to favorable shifting of the THV away from the coronary ostia. A bicuspid virtual planning algorithm accounting for 83.4% THV underexpansion, resulting in an 11.9% taller frame and translation of the THV away from the calcified raphe (mean valve shift 6.6 mm) achieved 86.7% sensitivity and 88.9% specificity for predicting redo-TAVR feasibility. CONCLUSIONS: Calcified raphe in left/right cusp fusion shifts the THV away from the coronary ostia, reducing coronary obstruction risk during redo-TAVR. Underexpansion causing increased THV frame height and valve shifting is common in bicuspid patients; a virtual planning algorithm accounting for these aspects can accurately assess redo-TAVR risk. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02628899.
- 4 November 2024
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Percutaneous Closure of Pulmonary Arteriovenous Malformation and Concomitant Patent Foramen Ovale for Cryptogenic Stroke
A 64-year-old woman presented with acute onset left-sided facial droop, left upper extremity paresis, and aphasia. Magnetic resonance imaging demonstrated acute infarction of the right thalamus. Clinical Images from Journal of Invasive Cardiology. cryptogenic stroke patent foramen ovale closure PFO Closure Pulmonary arteriovenous malformations
- 4 November 2024
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Percutaneous Closure of Pulmonary Arteriovenous Malformation and Concomitant Patent Foramen Ovale for Cryptogenic Stroke
A 64-year-old woman presented with acute onset left-sided facial droop, left upper extremity paresis, and aphasia. Magnetic resonance imaging demonstrated acute infarction of the right thalamus. Clinical Images from Journal of Invasive Cardiology. cryptogenic stroke patent foramen ovale closure PFO Closure Pulmonary arteriovenous malformations
- Top Cited PapersOpen Access
- 21 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (21) , 1627-1638
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown. METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of P =0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P =0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P <0.05). CONCLUSIONS: Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04509674.
- 21 May 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (21) , 1627-1638
Top Cited PapersOpen AccessEffect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown. METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of P =0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P =0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P <0.05). CONCLUSIONS: Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04509674.
- 1 August 2023
- Vol. 35 (8)
Diagnosis Related Group and Outcomes Following Transcatheter Aortic Valve Implantation
BACKGROUND. The association between Medicare Severity -Diagnosis Related Group (DRG) and early and intermediate -term outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) has not been well studied. We aimed to assess the relationship between DRG and 30 -day and 1 -year mortality in patients undergoing TAVI. METHODS. The study population included 289 patients with severe symptomatic AS who underwent TAVI from December 2015 to June 2018 at an academic tertiary care medical center. Patients were categorized as DRG 266 or DRG 267, specifying TAVI with or without major complication or comorbidities respectively. RESULTS. Of the 289 patients, 182 patients (63.0%) were classified under DRG 267 and 107 patients (37.0%) under DRG 266. The DRG 266 group had longer hospital lengths of stay and higher rates of discharge to a skilled nursing facility. While rates of in -hospital and 30 -day mortality were similar in both DRG groups, the DRG 266 group had higher 1 -year allcause mortality (26.2% vs 8.8%, p<0.001). In multivariable analysis, serum creatinine (OR 1.42, 95%CI 1.05-1.93) was the only independent predictor of 1 -year mortality in the DRG 266 group while atrial fibrillation (OR 3.04, 95%CI 1.03-8.92) was the only independent predictor of mortality in the DRG 267 group. CONCLUSIONS. In this prospective registry of patients undergoing TAVI, while rates of in -hospital and 30 -day mortality were similar in both DRG 266 and 267 groups, the DRG 266 group had higher 1 -year all -cause mortality. Distinct predictors of mortality in each DRG group exist.
- 1 August 2023
- Vol. 35 (8)
Diagnosis Related Group and Outcomes Following Transcatheter Aortic Valve Implantation
BACKGROUND. The association between Medicare Severity -Diagnosis Related Group (DRG) and early and intermediate -term outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) has not been well studied. We aimed to assess the relationship between DRG and 30 -day and 1 -year mortality in patients undergoing TAVI. METHODS. The study population included 289 patients with severe symptomatic AS who underwent TAVI from December 2015 to June 2018 at an academic tertiary care medical center. Patients were categorized as DRG 266 or DRG 267, specifying TAVI with or without major complication or comorbidities respectively. RESULTS. Of the 289 patients, 182 patients (63.0%) were classified under DRG 267 and 107 patients (37.0%) under DRG 266. The DRG 266 group had longer hospital lengths of stay and higher rates of discharge to a skilled nursing facility. While rates of in -hospital and 30 -day mortality were similar in both DRG groups, the DRG 266 group had higher 1 -year allcause mortality (26.2% vs 8.8%, p<0.001). In multivariable analysis, serum creatinine (OR 1.42, 95%CI 1.05-1.93) was the only independent predictor of 1 -year mortality in the DRG 266 group while atrial fibrillation (OR 3.04, 95%CI 1.03-8.92) was the only independent predictor of mortality in the DRG 267 group. CONCLUSIONS. In this prospective registry of patients undergoing TAVI, while rates of in -hospital and 30 -day mortality were similar in both DRG 266 and 267 groups, the DRG 266 group had higher 1 -year all -cause mortality. Distinct predictors of mortality in each DRG group exist.
- 4 July 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 201, 375-377
Predicting Long-Term Outcomes After Aortic Valve Replacement
- 4 July 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 201, 375-377
Predicting Long-Term Outcomes After Aortic Valve Replacement
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100687
A-23 | Gender Disparities in Cardiovascular Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100687
Open AccessA-23 | Gender Disparities in Cardiovascular Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions